Get started
Author

Melissa Hamilton

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients
2018 · Gregory Y.H. Lip, Allison Keshishian, et al. · Stroke · 324
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice
2017 · Xiaoyan Li, Steve Deitelzweig, et al. · Thrombosis and Haemostasis · 160
PDF
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
2022 · David Cella, Robert J Motzer, et al. · The Lancet Oncology · 88
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
2018 · Derek Weycker, Xiaoyan Li, et al. · Thrombosis and Haemostasis · 46
PDF
Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation.
2016 · Sumesh Kachroo, Melissa Hamilton, et al. · PubMed · 39
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach
2018 · Xiaoyan Li, Allison Keshishian, et al. · PLoS ONE · 37
PDF
Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation
2017 · Shuqian Liu, Xiaoyan Li, et al. · Current Medical Research and Opinion · 25
PDF
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence
2016 · Tereza Lanitis, Robert Leipold, et al. · Clinical Therapeutics · 23
Venous Thromboembolism Prophylaxis and Clinical Consequences in Medically Ill Patients
2013 · Onur Baser, Xianchen Liu, et al. · American Journal of Therapeutics · 23
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
2022 · Johannes Alfred Witjes, Matthew D. Galsky, et al. · European Urology Oncology · 21
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
2023 · Dirk Schadendorf, Hussein Tawbi, et al. · European Journal of Cancer · 20
PDF
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease
2018 · Renato D. Lopes, Jan Steffel, et al. · The American Journal of Medicine · 18
Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States
2014 · Xianying Pan, Teresa A. Simon, et al. · Journal of Thrombosis and Thrombolysis · 16
PDF
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
2017 · Tereza Lanitis, Robert Leipold, et al. · BMC Health Services Research · 15
PDF
Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.
2021 · David Cella, Toni K. Choueiri, et al. · Journal of Clinical Oncology · 14
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
2022 · Timothy Baker, Helen Johnson, et al. · PharmacoEconomics - Open · 11
PDF
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
2023 · Bradley McGregor, Daniel M. Geynisman, et al. · European Urology Oncology · 10
PDF
Treatment Patterns and Outcomes Following Disease Progression on Anti-PD-1 Therapies for Advanced Melanoma
2022 · Beth L Nordstrom, Melissa Hamilton, et al. · Future Oncology · 9
Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation
2017 · Ping G. Tepper, Xianchen Liu, et al. · Stroke · 9
PDF
The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214
2024 · David Cella, Toni K Choueiri, et al. · The Oncologist · 8
PDF
Real-world Comparison of Inpatient Bleeding Risk, Bleeding-related Hospitalization Rates and Costs Among Non-valvular Atrial Fibrillation Patients on Apixaban, Dabigatran, Rivaroxaban: Cohorts Comprising New Initiators And/or Switchers From Warfarin
2016 · Ping Tepper, Jack Mardekian, et al. · Journal of the American College of Cardiology · 7
PDF
Correction: Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses
2012 · Joseph T. Bruder, Elena Semenova, et al. · PLoS ONE · 7
PDF
Overall Survival in the Real-World and Clinical Trials: A Case Study Validating External Controls in Advanced Melanoma
2022 · James Signorovitch, Andriy Moshyk, et al. · Future Oncology · 6
Real-world treatment patterns and sequencing for metastatic renal cell carcinoma (mRCC): Results from the Flatiron database.
2021 · Saby George, Jillian Faccone, et al. · Journal of Clinical Oncology · 6
Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results.
2022 · David Cella, Robert J. Motzer, et al. · Journal of Clinical Oncology · 4
Works count: 54
Citation count: 963
H-index: 14
I10-index: 17
Year
Topic
Type